Chae Chang-Suk, Teran-Cabanillas Eli, Cubillos-Ruiz Juan R
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Cancer Immunol Immunother. 2017 Aug;66(8):969-977. doi: 10.1007/s00262-017-1958-2. Epub 2017 Feb 18.
Immune-based therapies that induce remarkable and durable responses against melanoma and lung cancer have unfortunately demonstrated limited success in ovarian cancer patients. This is likely due to the exceptional immunoregulatory nature of ovarian tumors, which employ numerous strategies to effectively suppress anti-tumor immunity. Here, we summarize a decade of research indicating that ovarian cancers possess an exquisite capacity to subvert the activity of host dendritic cells (DCs) as a key mechanism to impede the development and maintenance of protective T cell-based immune responses. Identifying, understanding, and disabling the precise mechanisms promoting DC dysfunction in ovarian cancer are, therefore, fundamental requirements for devising the next generation of successful immunotherapies against this devastating malignancy.
不幸的是，在黑色素瘤和肺癌患者中能诱导显著且持久反应的免疫疗法，在卵巢癌患者身上的成功率却有限。这可能是由于卵巢肿瘤具有特殊的免疫调节特性，它采用多种策略有效地抑制抗肿瘤免疫。在此，我们总结了十年的研究，表明卵巢癌具有精巧的能力来颠覆宿主树突状细胞（DCs）的活性，这是阻碍基于T细胞的保护性免疫反应发展和维持的关键机制。因此，识别、理解并消除促进卵巢癌中DC功能障碍的精确机制，是设计针对这种毁灭性恶性肿瘤的下一代成功免疫疗法的基本要求。
